Pfizer Beats Q1 Profit Estimates on Strong Eliquis Sales Performance

Key Facts

Pfizer reported first-quarter revenue of $14.5 billion, representing a 5% year-over-year increase and exceeding analyst estimates of $13.84 billion. The growth was primarily fueled by sustained demand for the blood thinner Eliquis and robust performance in its oncology division. Notably, new drug launches played a critical role in offsetting the decline in COVID-19 related product sales during the quarter. The company reaffirmed its full-year 2026 financial guidance, signaling long-term confidence in its strategic trajectory. Pfizer is increasingly relying on both recently acquired products and new launches to mitigate the impact of looming patent cliffs. Additionally, operational efficiencies contributed to boosting profit margins beyond Wall Street expectations. These results reflect Pfizer's successful pivot toward its core portfolio to ensure sustainable growth in the post-pandemic era.

Version History